Scholarlink

<p>Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune Effector Cell–associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Sofía Rincón-López,
  • Ricardo García-Muñoz,
  • Johelys Atencio-Matos,
  • Olalla Pereda-Sainz,
  • Javier Larreina-Pérez,
  • Andrea Campeny-Najara,
  • Pilar Herrera Pérez,
  • Montserrat Hernández-Pérez,
  • Jesús Feliu,
  • Ada Esteban-Figuerola

摘要

Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.